FindTrial
Sign In

Fluorine F 18 DCFPyL

DRUG3 trials

Sponsors

Andrei Iagaru, Jonsson Comprehensive Cancer Center, Northwestern University

Conditions

PSA Level Greater Than 0.2PSA Level Greater Than or Equal to TwoPSA ProgressionProstate AdenocarcinomaProstate CarcinomaRecurrent Prostate CarcinomaStage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage II Prostate Cancer AJCC v8

Phase 2

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
WithdrawnNCT04910425
Northwestern UniversityProstate Carcinoma
Start: 2023-06-17End: 2028-07-31Updated: 2025-10-21

Phase 3

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
TerminatedNCT04457245
Jonsson Comprehensive Cancer CenterStage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 +6
Start: 2020-08-14End: 2023-01-10Updated: 2023-01-17

Unknown Phase

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
NCT03501940
Andrei IagaruProstate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two +2
Updated: 2022-01-21

Related Papers

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
Journal of Nuclear Medicine2024-04-258 citations
Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.
Journal of Clinical Oncology2024-01-292 citations
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial
BMC Cancer2022-03-0820 citations
Abstract CT257: Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study Protocol
Cancer Research2021-07-01
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
2021-05-0718 citations
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.
Journal of Clinical Oncology2021-02-201 citations
Prospective evaluation of <sup>18</sup>F-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
Journal of Clinical Oncology2020-05-20